Opthea Ltd - ESG Rating & Company Profile powered by AI
This webpage contains a zero-cost ESG report for Opthea Ltd. The Sustainability score for Opthea Ltd indicates the company's reporting of the UN SDGs. The ESG score covers seventeen UN Sustainable Development Goals including: 'Quality Education', 'Reduced Inequalities' and 'Peace, Justice & Strong Institutions'.
Opthea Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 0.0 and governance score of 3.2.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | Opthea Ltd | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Opthea Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Opthea Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Opthea Ltd report the average age of the workforce?
Sign up for free to unlockDoes Opthea Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Opthea Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Opthea Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Opthea Ltd offer flexible work?
Sign up for free to unlockDoes Opthea Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Opthea Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Opthea Ltd conduct supply chain audits?
Sign up for free to unlockDoes Opthea Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Opthea Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Opthea Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Opthea Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Opthea Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Opthea Ltd disclose water use targets?
Sign up for free to unlockDoes Opthea Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Opthea Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Opthea Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Opthea Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Opthea Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Opthea Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Opthea Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Opthea Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Opthea Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Opthea Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Opthea Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Opthea Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Opthea Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Opthea Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Opthea Ltd disclose its waste policy?
Sign up for free to unlockDoes Opthea Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Opthea Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Opthea Ltd disclose energy use targets?
Sign up for free to unlockDoes Opthea Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Opthea Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Opthea Ltd
These potential risks are based on the size, segment and geographies of the company.
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.